Olaparib and Tezacaftor/ivacaftor and ivacaftor
Determining the interaction of Olaparib and Tezacaftor/ivacaftor and ivacaftor and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Olaparib may increase the blood levels and effects of ivacaftor. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin). The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.
MANAGEMENT: Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: ivacaftor / tezacaftor
Brand name: Symdeko, Symdeko 4-Week
Synonyms: Tezacaftor/ivacaftor and ivacaftor (Oral)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Olaparib-TGQ 30PSE/3BRM/15DM
- Olaparib-TGQ 7.5PEH/4BRM/15DM
- Olaparib-TGT First Aid Antibiotic
- Olaparib-TGT First Aid Cleansing
- Olaparib-TH Antibiotic + Pain Relief
- Olaparib-Thalidomide
- Tezacaftor/ivacaftor and ivacaftor-Olaparib Capsules
- Tezacaftor/ivacaftor and ivacaftor-Olaparib Tablets
- Tezacaftor/ivacaftor and ivacaftor-Olaratumab
- Tezacaftor/ivacaftor and ivacaftor-Olaratumab Intravenous
- Tezacaftor/ivacaftor and ivacaftor-Oleptro
- Tezacaftor/ivacaftor and ivacaftor-Oleptro Oral